Paul Swiecicki is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 494 publications with 3,662 citations (h-index 29); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
B1 Floor Cancer Recp C
Ann Arbor, MI 481095912
Telephone
734-647-8902Registry record last updated 21 Jul 2022.
Clinical trials
- Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
Sponsor: University of Michigan Rogel Cancer Center
- Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
Sponsor: SWOG Cancer Research Network
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma Europe LtdProgram year20251 payment
- Astellas Pharma Global DevelopmentProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
41.9%Opioid Agonist18.6%Oxycodone Hcl56%Fentanyl22%Morphine Sulfate22%Part D<11 patientsPhenothiazine14.1%Prochlorperazine Maleate100%Part D≥34 patients+ 2 more classes in this area
Metabolism & gastrointestinal
38.5%Serotonin-3 Receptor Antagonist25.8%Ondansetron Hcl71%Ondansetron Odt29%Part D<11 patientsCorticosteroid8.9%Prednisone100%Part D≥14 patients+ 1 more class in this area
Cancer & immunology
7.2%Hedgehog Pathway Inhibitor7.2%Erivedge100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
Practical Radiation Oncology
2024 - Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
International Journal of Radiation Oncology*Biology*Physics
2024 - Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”